The Journal of Bone and Joint Surgery (American) 86:519-524 (2004)
© 2004 The Journal of Bone and Joint Surgery, Inc.
Steroid Treatment and the Development of Scoliosis in Males with Duchenne Muscular Dystrophy
Benjamin A. Alman, MD, FRCSC1,
S. Naweed Raza1 and
W. Douglas Biggar, MD, FRCPC2
1 Department of Surgery and Program in Developmental Biology, The Hospital for
Sick Children, 555 University Avenue, Toronto, ON M5G 1X8, Canada. E-mail
address for B.A. Alman:
benjamin.alman{at}sickkids.ca
2 Bloorview MacMillan Children's Centre, 350 Rumsey Road, Toronto, ON M4G 1R8,
Canada
Investigation performed at the Bloorview MacMillan Children's Centre,
The Hospital for Sick Children, and the University of Toronto, Toronto,
Ontario, Canada
The authors did not receive grants or outside funding in support of their
research or preparation of this manuscript. They did not receive payments or
other benefits or a commitment or agreement to provide such benefits from a
commercial entity. No commercial entity paid or directed, or agreed to pay or
direct, any benefits to any research fund, foundation, educational
institution, or other charitable or nonprofit organization with which the
authors are affiliated or associated.
Background: Scoliosis due to progressive muscle weakness occurs in
almost all males with Duchenne muscular dystrophy, and it progresses
relentlessly. Previous studies have shown that corticosteroid treatment slows
the decline in muscle strength and stabilizes muscle strength in patients with
this disease. We hypothesized that steroids may also attenuate the development
of scoliosis. The purpose of this study was to compare the prevalence of
scoliosis in male patients with Duchenne muscular dystrophy who received
steroids with a control group of such patients who did not.
Methods: A group of seven to ten-year-old boys with Duchenne
muscular dystrophy who were able to walk were enrolled in a nonrandomized
comparative study to determine the effect of deflazacort (a derivative of
prednisone) on muscle strength and pulmonary function. Thirty patients were
treated with deflazacort (treatment group), and twenty-four were not (control
group). The patients were matched for age and pulmonary function at baseline.
To assess the development of scoliosis, the patients in each group were
followed for at least five years. Survival curves were plotted to determine
the chance of scoliosis of 20° developing. The difference between the
groups with respect to the chance of scoliosis developing was determined with
Kaplan-Meier analysis.
Results: A curve of 20° developed during the follow-up
period in sixteen (67%) of the twenty-four patients in the control group but
in only five (17%) of the thirty patients in the treatment group. Fifteen of
the twenty-four patients in the control group underwent spine surgery, at a
mean age of thirteen years, whereas only five of the thirty patients in the
treatment group underwent spine surgery, at a mean age of fifteen years.
Kaplan-Meier analysis demonstrated a significant difference between the two
groups with regard to development of scoliosis of 20° (p < 0.001).
Cataracts developed in ten patients in the treatment group, and stress
fractures developed in three patients in the treatment group. Patients in the
treatment group weighed a mean of 3.7 kg more than did those in the control
group.
Conclusions: Steroid treatment slows the progression of scoliosis in
males with Duchenne muscular dystrophy; however, longer-term evaluation will
be necessary to determine if the treatment prevents the development of
scoliosis or just delays its onset. At the very least, steroid treatment
delays the need for spinal surgery.
Level of Evidence: Therapeutic study, Level II-1
(prospective cohort study). See Instructions to Authors for a complete
description of levels of evidence.

CiteULike Connotea Del.icio.us Facebook Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. J. Dunbar, A. Howard, E. R. Bogoch, J. Parvizi, and H. J. Kreder
Orthopaedics in 2020: Predictors of Musculoskeletal Need
J. Bone Joint Surg. Am.,
September 1, 2009;
91(9):
2276 - 2286.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. M. King, R. Ruttencutter, H. N. Nagaraja, V. Matkovic, J. Landoll, C. Hoyle, J. R. Mendell, and J. T. Kissel
Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy
Neurology,
May 8, 2007;
68(19):
1607 - 1613.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. A. Karol
Scoliosis in Patients with Duchenne Muscular Dystrophy
J. Bone Joint Surg. Am.,
February 1, 2007;
89(suppl_1):
155 - 162.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. D. Biggar
Duchenne Muscular Dystrophy
Pediatr. Rev.,
March 1, 2006;
27(3):
83 - 88.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. S. Kocher and P. O. Newton
What's New in Pediatric Orthopaedics
J. Bone Joint Surg. Am.,
May 1, 2005;
87(5):
1171 - 1179.
[Full Text]
[PDF]
|
 |
|
|